0:04
Hi everyone. Welcome to Rheumatology Roundup.
0:07
This is the 2026 edition. We're just back from Orlando where the ACR annual meeting took place.
0:18
And we've got a lot to talk about. I'm Jack Cush in Dallas, Texas with RheumNow.
0:24
Arty Gavin, San Diego. So, we've had 48 hours to recover from the meeting and we're going to share with you our fast walking, fast talking version of ACR Convergence 2026.
0:40
We're going to discuss the presentations, abstracts, and posters that we found interesting at this year's meeting.
0:48
It's solely chosen by us. So the bias is our bias and our interest.
0:53
In the past we've warned you about please do not reproduce and share this stuff.
0:58
You know what? Go ahead, reproduce it and share it.
0:59
Why do we care? Arty, what do you think of the meeting?
1:05
It was busy. A lot of sessions to go to.
1:09
What's your take on the meeting? Yeah, it was busy.
1:12
It did seem a little bit less crowded in the aisles at the posters.
1:15
And I know you and I, we just love the posters.
1:19
That's the heart of the meeting. Thank goodness now they're back to the actual way it's always been — big full-size posters that someone could stand in front of and give the presentation and then you can interact with them.
1:30
I wasn't happy that they were competing with the posters.
1:35
They had some sessions including plenary sessions that competed with the poster session.
1:41
I think the poster session should be sacrosanct and that gives you a chance to talk to the authors and meet old friends and just schmooze in general.
1:49
So I was kind of a little bummed out by that, but it was a great meeting.
1:54
A lot of great information as always. Too much information across the breadth of rheumatology. So it was really good.
2:01
So how many — I mean, there was over almost 3,000, right?
2:04
What was the number? 2,980 abstracts accepted.
2:09
Yeah. So there's their problem. How can you get all that out there without having considerable overlap and shortchanging someone?
2:17
But I agree. Don't short-change the posters.
2:19
Don't short-change the plenaries. Everything else should be a free-for-all.
2:23
Anyway, what's your first one that you really liked, Arty?
2:26
All right. First one I like is abstract 1822.
2:30
And this is clonal hematopoiesis and giant cell arteritis.
2:35
So kind of an increasingly hot topic, one we never learned about, but we're seeing more and more.
2:41
You think of VEXAS and the idea of somatic mutations.
2:45
These are mutations that happen after we're born, often later in life.
2:50
We think of these — they often occur in populations of cells, not in all cells, particularly in the myeloid cells.
2:56
And of course if you think of clonal proliferation you think of cancer, and cancers are there, but there are a lot more changes that
3:08
seem to be associated with our diseases, and that includes the mosaic errors of immunity — they're calling them sometimes things like a chromosome dropping
3:18
out, like the mosaic loss of Y chromosome.
3:22
But here they looked for clonal hematopoiesis, which you can actually do now.
3:27
It's clear that it happens in older persons.
3:30
So about 5% of people who are 60 or older, 10% of people over 80.
3:34
And they're associated with some diseases.
3:37
There was just a publication in the most recent Arthritis and Rheumatology about association with seropositive RA among older persons.
3:45
This was a great presentation. It was an oral presentation and they did a couple of things.
3:51
They did a meta-analysis of some databases including the All of Us registry from the US.
3:57
And what they found is that in GCA — giant cell arteritis — half the people had clonal hematopoiesis.
4:06
They had changes in certain genes; particularly represented were a gene DNMT3A and TET2.
4:16
Fascinating was that the mutated persons had not only a greater chance of developing GCA but it was more severe with more relapses.
4:26
They did some other fancy things which I think was really fantastic.
4:29
They looked at blood with RNA-seq but also temporal artery biopsies.
4:35
What they found was that in the biopsy specimens there was an overproduction of inflammatory cytokines, and that was derived from a perturbation in the development of macrophages such that the macrophages went to a more inflammatory type of phenotype.
4:53
And in the biopsies they found these inflammatory macrophages clustered around defects in the internal elastic lamina, which is of course the hallmark — the pathophysiological hallmark — of giant cell arteritis.
5:07
So I think it's a nice story. We discussed it at the meeting.
5:11
This might be something that might change practice.
5:13
We know in GCA it's — do the patients relapse or do they not?
5:18
Do you treat them with steroids and other steroid-sparing agents beyond the time they're in remission or not?
5:23
And I think it might be something that we actually do in the clinic.
5:26
So I found this also really interesting, and we have talked about CHIP studies in the past.
5:37
What we do know is that clonal hematopoiesis mainly associates with aging but it's got a lot of other conditions as well — cardiovascular disease, malignancies, inflammatory diseases — but it has been linked to GCA.
5:49
And I love the story of how you can take the reasonable linkage at 50% to the pathologic story in the end.
5:59
One of the other sessions that I was at — I think it's 2885 or 2888 — was another oral presentation on CHIP, where they
6:10
said it had a modest to moderate correlation with GCA, but they showed you that different patterns of mutations that were seen might be associated
6:21
with different manifestations of GCA.
6:25
It started to look a lot like for me the anti-histone story in lupus and drug-induced lupus — meaning that there are many different histones,
6:34
actually there's at least five and subtypes and whatnot, and the patterns that associate with drug-induced lupus are different for the different drugs and also
6:43
different for lupus.
6:45
So it gets kind of confusing. You just can't order a CHIP and say, "Oh, it could be vasculitis."
6:50
It's got a lot of associations. So there's still a lot of work here in making the associations clinically meaningful.
6:58
But still I like the story that this might be an earliest breakdown that leads to the pathology that leads to the syndrome. Yeah, absolutely.
7:10
So then, kind of coupled with that — if that's going to interest your scientific mind, now I'm going to scratch your clinical head with abstract 0172.
7:21
It was a poster, a retrospective nationwide French study of GCA patients with a normal CRP.
7:33
You know, I walked by this poster and said, "Wait a second.
7:37
I don't like this at all because I always argue with someone who tries to make a case for this."
7:42
So I looked at this and it's got some credibility to it.
7:47
It's also got some holes in it. To be in the study — they had 74 patients, by the way, with normal CRP GCA —
7:55
they had to be over age 50, they had to have a physician-adjudicated GCA, and they had to have a diagnosis supported by either temporal
8:01
artery biopsy, done in almost 70% of patients — 67% had a positive temporal artery biopsy — and then a bunch of them had positive
8:15
imaging either ultrasound or PET.
8:16
Again, you had to have a normal baseline CRP to get in.
8:21
74 patients — they were, as you'd expect, 73 years of age.
8:24
They had 170 high-CRP GCA controls, and these patients who had a normal CRP met 2022 ACR/EULAR criteria for GCA.
8:34
The temporal artery biopsy was positive in almost 70%.
8:39
The PET-CT showed large vessel involvement compatible with GCA in 60% of the cases that were tested.
8:48
Compared to the controls that had high CRP, the low-CRP patients had fewer systemic symptoms.
8:54
None of them had fever versus 29% in the high-CRP group.
9:00
They had less fatigue, less weight loss, and they were less likely to have PMR manifestations — 24% versus 47%.
9:07
But the other interesting thing about these normal-CRP patients is that they had more ischemic complications, more ischemic strokes — maybe three times the amount of ischemic strokes — more ophthalmic symptoms.
9:21
So while they did well with less relapses, it was a slightly different picture.
9:29
Did they really have GCA? Are those strokes inflammatory or atherosclerotic?
9:34
Are these people who just can't mount the CRP?
9:39
Is this possible? This report would say yeah, it's possible.
9:43
I still would worry about making a diagnosis without an elevated CRP or sed rate.
9:46
Yeah, you want them to be very classic and of course having the temporal artery biopsy proof for sure.
9:54
But yeah, things are really changing in giant cell arteritis and a lot more information — we may be practicing differently, including looking for some of these somatic mutations.
10:06
So my next poster is 1407, and this is longitudinal patterns of difficult-to-treat rheumatoid arthritis.
10:15
Kind of a buzzword lately, isn't it? Difficult-to-treat started in rheumatoid arthritis but now we have difficult-to-treat axial SpA, difficult-to-treat psoriatic arthritis, difficult-to-treat lupus, etc.
10:29
It's a concept that I think is fascinating because I think all of us can define what difficult-to-treat is — if you said which of
10:35
your patients are difficult to treat you could give the names of the patients and the clinical cases — but translating that into a definition
10:46
that can then be used to classify people into a clinical research study, it gets a little trickier.
10:51
EULAR has published a definition of difficult-to-treat in RA, which is not unreasonable at all.
10:58
But I like this abstract because it points out some potential difficulties with that.
11:05
So they looked in their cohort — in the Leuven, Belgium cohort — and went to the clinic and found 103 patients who met the EULAR definition of difficult-to-treat.
11:16
They followed them longitudinally as they do in the clinic.
11:18
Bottom line is what they found is about half the patients — 48.5% — stayed difficult-to-treat over up to five years of follow-up.
11:30
So are they the real difficult-to-treat patients?
11:35
A challenge if you think of putting patients in a study is that the other half of patients came in and out of the difficult-to-treat definition.
11:44
A very small subset of them — 4% — fell out and were never difficult-to-treat again.
11:49
You wouldn't want to put those patients in a clinical research study because they're better.
11:53
Others went in and out at various amounts of time.
11:56
And it wasn't strictly related to treatment.
11:59
So it's a challenge to say — and we're hearing now some newer therapies saying, "Well, maybe we could be used in difficult-to-treat RA," which sounds good, but it's hard.
12:12
And I think this shows us that it's really quite dynamic. People change over time.
12:20
When I first saw this and looked at this, it immediately reminded me of a paper I looked up as a fellow.
12:28
I had to go to the library archives to find this — like a 1958 paper about changes in RA joint exams in a 7-day period.
12:39
For our younger listeners, could you tell them what a library is?
12:43
Oh, yeah. It's a building — it used to be inside the medical school, now it's like a half mile away.
12:52
And they have these books. But the idea is it is the repository of all great past research.
13:01
And this paper from 1958 showed that tender joint count and swollen joint counts vary day-to-day.
13:06
The other corollary to this — I like the recent PMR and GCA pivotal studies where the endpoint is sustained remission, that you've got to be in remission and under a certain number for like six months — a really high bar to achieve.
13:26
The same can be said for D2T RA. While half of them have that persistent state, the others are bouncing in and out, and it speaks to the variance that we'll see visit-to-visit, day-to-day, week-to-week.
13:39
But I also tend to think that while 10% to 15% of our patients will have difficult-to-treat RA, they may bounce in and out, but those people are not going to be the people who you would clearly say are in low disease activity or are in remission.
13:55
They're on the other end of the spectrum and there's still going to be people we worry about.
14:00
I would love for them to take this the next step and show what happens to people in persistent or frequent or relapsing — or once-only D2T status — and of course that is based on the seven EULAR criteria published by Nagy et al. in 2021 in Annals of Rheumatic Diseases.
14:20
But I think that's what we're seeing now since the EULAR definition — research like this that's really going to help us in making our choices for therapy and going to the other diseases.
14:31
It's certainly relevant to the other diseases where we also want to get at the difficult-to-treat population.
14:36
Yeah. And those are the people where we're just looking for some guidance, and this kind of research is really important in that regard.
14:44
Speaking of guidance — you know, one of the big questions now with AI having arrived is should AI be used in the course of seeing patients?
14:55
Is it a clinical tool that can be used real-time in a dynamic way?
14:59
There was a plenary session on the first day.
15:02
Pitalia and colleagues, abstract 0869, looked at the clinical utility — the veracity and maybe pitfalls — of using five different AI platforms in rheumatology cases.
15:23
So they constructed 60 standardized scenarios based on or conforming to ACR and EULAR guidelines and recommendations for diseases like RA, lupus, gout, vasculitis, osteoporosis, and SpA.
15:54
And in the questions that they posed to these different platforms — they posed the same question to multiple platforms including ChatGPT, Gemini, Claude, Perplexity,
15:56
and Open Evidence — they asked questions about diagnosis, treatment selection, steroid tapering, vaccination complications, and in the end they all did pretty well, but
16:00
they really did vary.
16:01
As far as conforming to ACR/EULAR guidelines, the best was Open Evidence at 91%.
16:09
Second best was ChatGPT at 89%. The worst was Perplexity at 75%.
16:15
So a significant 16 percentage-point spread.
16:17
And what you worry about most is when AI hallucinates — meaning it gives you non-factual information.
16:24
And there was a big difference there, with a range of hallucination rates of 3.8% to 18.1%.
16:30
Best was with Open Evidence. Worst was with Gemini and Perplexity at 15 and 18%.
16:40
So the point is that it'll help you, but it's got holes in it.
16:44
The authors recommended: one, verify every citation from AI; two, cross-check every dose and dosing regimen; three, confirm whether what is being recommended conforms to guidelines; and recognize that AI can only give you a first draft, not a final decision.
17:02
So two quick questions come to mind. One, can you ask AI to check on how good the AI is — like ask Claude to check up on ChatGPT?
17:15
And the second is, for your billing, do you get to bill more or do you have to bill less if you're using AI?
17:20
Yeah, I think the more we ask these questions, the more we won't be doing any billing in the future.
17:29
And someone named Claude will be billing for us.
17:34
I'm hearing different things. Against the tsunami of white-haired, gray-haired, retiring rheumatologists like me — we're not using much AI.
17:45
But the rheumatology fellow under 45, she's using a fair amount of this.
17:51
Again, I think it can get you good answers.
17:55
My opinion is stick with Open Evidence. ChatGPT seems to be faster and give you more complete educational answers.
18:03
I like Claude if you're writing things and doing documents and doing research as well.
18:08
But we're still going to learn more. I like that this was being presented.
18:12
I could have found fault with this, but I thought there were more positives here than faults. Yeah, interesting stuff.
18:22
So my next poster was one that — I think not super sexy or new, but I think very important.
18:29
In fact, I already shared this poster with our fellows because I think it's a new analysis of an issue that has been part of rheumatology forever.
18:40
This is poster 2450, excuse me. This is synovial fluid white cell counts in inflammatory arthritis.
18:50
So many of us grew up saying, well, what's inflammatory arthritis?
18:55
Is it more than 2,000 cells per microliter?
18:58
Is it more than 2,500? Is it more important to have the percentage of polymorphonuclear leukocytes or neutrophils — 75% or more?
19:06
And I think it's quite relevant. You will sometimes hear people say, "Well, that can't be gout because the cell count was only this," or "That can't be rheumatoid arthritis because the cell count was too high."
19:23
It turns out there's quite a lot of spread.
19:26
This is a poster from the Hospital for Special Surgery, and they know their way around joint aspirations.
19:34
What they did is look at the aspirations they had at a single center — nearly 2,000 joint aspirations — over 2017 to 2023.
19:44
In the past they had said that 1,400 mononuclear cells per microliter may be a way to classify high versus low inflammatory.
20:01
And what they found was a spread — and they then had the diagnoses, which were carefully adjudicated.
20:09
They had OA, lupus, CPPD, SpA, PsA, rheumatoid arthritis, gout, reactive arthritis, and septic arthritis.
20:17
As you'd expect, many of the people with OA had counts less than 1,400.
20:25
So 1,400 seems to be a nice way to do it.
20:26
Less than 10% of OA patients have greater than 1,400.
20:32
Contrariwise, of the septic arthritis patients, fewer than 5% have a count less than 1,400.
20:40
The others are sort of in between. Interestingly, CPPD was much lower than gout when you look at the cell count.
20:47
They have a violin plot of the individual data, the means and the spread.
20:54
They also looked at aspirations done the same day — sometimes that happens, especially if people are hospitalized — and they're largely concordant.
21:08
So 1,400 cells per microliter may be a nice way to think about it.
21:12
Always important to know that there are outliers, some more than you would have anticipated.
21:19
So I think it's a great poster. I'm going to keep that and share it and look forward to the paper where they get into more detail.
21:25
Yeah, if you're a synovial fluid nerd, if you love to teach on evaluation of patients with musculoskeletal complaints, or if you're a fellow, you really have to look up this abstract just to see the figures that'll show you the numbers and the spread.
21:43
I'm looking at it now, and the average WBC count in OA was like 700.
21:50
And it's really important to know what you're dealing with.
21:55
It also tells you that in patients with septic arthritis, yes, they are very high — 60,000 and above — but there's a lot that go all the way down to 1,000, and it tapers down on those violin plots.
22:09
So this is a really instructive piece that I'm going to use in my teaching going forward.
22:17
I was really surprised at this because I've been very dogmatic about that 2,000 number.
22:24
I mean, I've been writing the chapter in Harrison's on the evaluation of the musculoskeletal complaint and putting in that 2,000 number for the last 25 years. Well, that's going to change.
22:36
Might this be somewhere AI could help — and say if this is the count, you have a 2% chance — give you an actual number, and then the more information you put in, the better?
22:50
I think that AI may be useful in something like this.
22:54
Absolutely. And the other thing I'd love to see on this — and maybe it'll come out with the paper — is the utility of the PMN percentage.
23:03
That's where we talk about infection going high, and higher at 85 and 90% the risk of infection goes way up.
23:10
I'd like to see that number included in the full report.
23:13
But that was really instructive. And a poster, right? Yeah, a poster. Lovely.
23:19
This was an oral presentation — abstract 0871 — from the great Philip Conaghan in Leeds.
23:33
This was the retatrutide study in knee OA patients who are obese.
23:37
This is a landmark study. I think it's a phase 3 study of a novel compound that's not yet FDA approved.
23:45
It is a triple agonist. What does that mean?
23:51
It targets GIP, GLP-1, and glucagon. You know the drugs that are out there — semaglutide is a single-agonist GLP-1 receptor agonist.
24:00
And then tirzepatide is a dual agonist — it's GIP/GLP-1.
24:04
Anyway, this is a once-weekly injection.
24:09
It was given to 445 non-diabetic obese adults with a BMI of greater than 27.
24:16
They had to have moderate to severe knee pain and Kellgren-Lawrence X-ray knee OA of grade 2 or 3.
24:23
And they either got placebo, 9 milligrams, or 12 milligrams — that's the order I'm going to present the outcomes.
24:31
9 milligrams, 12 milligrams, or placebo, all given once a week.
24:35
These people were very obese — over 250 pounds, BMI average of 40.4.
24:41
Baseline WOMAC pain score was basically 6 out of 10.
24:45
And at week 68, the WOMAC pain score dropped by 4.5 points for 9 milligrams, 4.4 for 12 milligrams, versus 2.4 for placebo, with changes as early as week 16.
24:59
The weight loss here was incredible — up to 71 pounds in some patients.
25:03
Weight loss was 26%, 29%, or 2% with placebo.
25:08
70% pain reduction was seen by 73% or 68% versus 26% in placebo.
25:16
And the triple-agonist therapy halved the CRP levels in over 50% of the patients that were on the drug.
25:27
It also lowered triglycerides. It had the expected side effects — mostly being nausea, some vomiting, very few serious adverse events at about 10% — and AEs leading to discontinuation were 13%, 18% versus 4%.
25:44
The point being that these people with pretty severe obesity and pain of at least 6 out of 10 dropped about 25% of their weight and dropped their pain scores by 4.5 points when they started out at 5.95.
26:01
I think this is tremendous data, and it follows up what happened the day before.
26:08
The RISE registry presented a combined analysis — if you use a GLP-1 drug in RA and PsA, they showed that yes, your RAPID3 got better, but the magnitude of improvement in that RISE study was modest compared to this.
26:24
Yeah, I think this is practice-changing, paradigm-changing.
26:31
Remember our orthopedic colleagues will tell patients, "You need a knee replacement — go lose 50 pounds, come back and see me."
26:39
This could well be that maybe this decreases the need for orthopedic surgery, and that changes the whole equation of the pharmacoeconomics of it.
26:51
I think it's kind of fascinating — do you go with a single agent like a single GLP-1?
26:57
Do you go with the dual or do you go with the new triple one if you want to lose weight?
27:02
Should you just go right to the one that's the strongest?
27:06
But getting back to practical issues of access, and maybe take the pill because I'm happier taking a pill than a shot.
27:13
But I think we talk about weight all the time with almost every patient, and I think now we can actually do something about it.
27:22
And it raises a question of — is it going to be us?
27:27
Are we the ones to prescribe this to our patients?
27:28
And I think we will be — psoriatic arthritis patients who don't see a bunch of other physicians, the OA patients that we have nothing to offer — maybe this is something to offer.
27:41
I'm glad you said that because I think the big question that everyone asks — it's rhetorical more than anything because there's no data, and it's going to be hard to disentangle — but do these drugs have an anti-inflammatory immunologic benefit?
27:54
That's all pontification. I think, as you said, the really greater question is who's going to do this.
28:02
And there are more and more rheumatologists — if you've seen the campaign we just did on obesity, a whole month on it — I was shocked at how many rheumatologists are experts in this field.
28:13
So this may be something that you'll become very familiar with if you see patients with obesity and any one of your rheumatic diseases.
28:21
So somewhat related, and I'm going to take a little bit of a mulligan — not a real mulligan because I was involved only very peripherally — but this is abstract 1360.
28:32
And this is the severity of MASLD — metabolic-associated steatotic liver disease — on a certain kind of new MRI — MRI PDFF — in psoriatic disease.
28:46
Does sex matter? This is work done by our UCSD chief and a real worldwide metabolomics expert, Dr. Monica Guma.
28:56
It was presented at the poster by one of our younger faculty, Dr. Quinn Wynn.
29:01
Basically collaborating with a lot of the liver people, 46 overweight and obese patients with psoriatic disease — psoriasis and/or psoriatic arthritis — were enrolled.
29:14
The blood tests were done and they did this new fancy MRI proton density fat fraction — the MRI PDFF — a way to establish the presence of hepatic steatosis.
29:28
What they found is that compared to age-matched persons, the PDFF was a little bit higher in the patients with psoriatic disease compared to the controls, but the difference was all in females.
29:42
So for the males there was no difference in the MRI PDFF between psoriatic disease and non-psoriatic disease, but a big difference in women — 13.8% with psoriatic disease versus 7.4% without.
29:59
And as we all know, sex is a very important topic in psoriatic arthritis, with the suggestion that there are differences in baseline characteristics and in the response to various therapeutics.
30:14
And now it looks like even comorbidities differ by sex, meaning that when you look at this study you have to look at the data a little bit differently — you have to look at how the apportionment of efficacy but also of tolerability and safety was across the sexes.
30:34
And we don't know why. Super interesting, very solid data from the group even on a small number of patients, and a very hot topic following up on what we were just talking about with obesity.
30:48
So remind me again — PDFF — it's a proton density fat fraction.
31:01
Fatty liver is a little tricky. Remember that now if you send someone to radiology, they will say yeah, it looks like fatty liver, but it's not like there's an ultrasound absolutely pathognomonic signature for that.
31:17
They can do the density which they do with a little ultrasonic machine.
31:22
There's the FIB-4, which takes some clinical things and suggests that you have fatty liver, which actually works out really well with just four laboratory measures.
31:32
But this I think is a step up in terms of actually establishing the diagnosis of fatty liver.
31:39
The gold standard of which has been biopsy, which you don't want to do if you don't have to.
31:45
So I think this technique hopefully will get more widely available because I think it is a step up in terms of really establishing the diagnosis.
31:53
And to start out studying this in psoriatic arthritis makes so much sense — with all their comorbidities, obesity is a big problem.
32:01
Population numbers on overweight and obesity are like 58–60%, but in PsA it's like 72–80%.
32:11
So we really need to get help there. And this is definitely going down that path.
32:20
I was wandering the poster floor and was approached by a bunch of people from the NIH saying, "You're going to cover our abstract tomorrow."
32:32
And I was like, "What — what's 2889?" — clonal lymphoid vasculitis with somatic SYK rearrangements.
32:41
And I thought to myself, why would I be doing that?
32:44
But they were basically telling me, "You've got to do it.
32:49
Look at it." And boy, I'm glad I did. This is data coming out of the NIH — Benjamin Turis, I think I got his name wrong, I'm sorry Benjamin — but it was a great presentation that he did.
33:03
He's working with a bunch of investigators at NIAMS.
33:05
And this was an oral presentation that probably should have been a plenary, because it's going to be a New England Journal article in a few weeks.
33:19
This is right up Dan Kastner's pedigree — he established himself as the father of autoinflammatory disease.
33:25
He would be so proud of these folks for all that they've done.
33:31
And Dan was the Gold Medal award winner at this year's ACR, posthumously.
33:35
Lots of tears in the audience when he got that award.
33:39
So very fitting that this is a new kind of VEXAS syndrome — another somatic mutation.
33:44
I asked them, "How did you find it?" Well, they got these patients who have hypereosinophilia, and they've got strange vasculitis — really dramatic vasculitis.
33:57
They had five who had not only this lymphocytic variant of hypereosinophilic syndrome but also had vasculitis with multiple aneurysms — big aneurysms, axillary, hepatic, spinal, coronary, vertebral — strokes and MIs in these people.
34:17
And they found an aberrant T-cell clone that was CD7-positive, CD4-positive, but strangely low CD3, absent CD3.
34:26
CD3 is the main marker we use for T-cell clones.
34:28
So they showed that when they did biopsies of the vasculature, they found these CD4 T-cells and an abundance of eosinophils — no granulomas, no giant cells.
34:44
And when they did further analyses they found these somatic mutations of SYK.
34:50
SYK is not normally very involved in T-cells, but these T-cells had ten-fold elevations of SYK.
34:56
So now this is like VEXAS — this is a very small subset, a very specialized subset.
35:02
I thought VEXAS was incredibly small and specialized, and in the few years that VEXAS has been out, I don't know of a rheumatologist who hasn't thought VEXAS or diagnosed several VEXAS cases.
35:12
So I think that this is how great science gets started.
35:16
Of course the question is how should these people be treated.
35:20
They have used traditional vasculitis medicines with some success, but they said it kind of burns out.
35:28
Peter Merkel, who was in the audience, asked — maybe we should be using fostamatinib, the SYK inhibitor, which was being tested in a number of things and stopped testing for not working and maybe some other issues.
35:40
But I think this is a really important study we should know about.
35:46
Yeah, fostamatinib is used by our hematology colleagues in thrombocytopenia.
35:53
And so yeah, the NIH has really been way out in front finding these rare but informative mutations that will hopefully lead to us being able to better treat the patients with these diseases.
36:12
So my next — I'm going to put two of them together because I think they're different but similar enough.
36:19
And this is the idea of are we going to have urinary biomarkers for lupus.
36:27
Lupus nephritis — incredibly important. We know that we like to have the biopsy to look at both the activity — using the activity index and the chronicity index.
36:39
Proteinuria is something we measure clinically and we certainly pay attention to that.
36:44
We like it to improve, but it's kind of imperfect and subject to other influences.
36:51
We also don't know what to do — we'd love to rebiopsy people potentially, but you don't want to do biopsies over and over.
37:00
They're invasive and potentially can be associated with some problems, particularly localized bleeding.
37:05
It doesn't happen a ton, but if there is a way to avoid those...
37:12
So these two posters are 1862 and 1232. So 1862 — a prospective randomized controlled study.
37:22
They did repeat biopsies on a randomized sample and looked at the urine protein-to-creatinine ratio.
37:29
And of course they found there was a discordance with disease activity based on the biopsy and the amount of proteinuria that was there.
37:41
And they came up with what I think is a new number that we all need to hold onto.
37:48
We had said 0.5 — below that maybe that was OK — 0.5 grams per gram.
37:54
What they found is that the best cutoff for UPCR — the urine protein-to-creatinine ratio — was 0.2.
38:01
Below 0.2, half the people had no activity — activity index of zero.
38:10
Above 0.2, there were no patients who had an activity index of zero.
38:17
In between 0.2 and 0.25 was kind of a no man's land.
38:21
They did have a couple of patients with high activity despite protein in that range.
38:25
So I think this is maybe a new standard — that 0.5 is no longer "don't worry, we don't need to think about it."
38:34
If you're below 0.2 I think maybe you don't need to proceed with further biopsy.
38:40
The second was a therapeutic study. They looked at urinary epidermal growth factor, which falls with tubular injury.
38:52
What they did was measure this in the obinutuzumab study — obinutuzumab, a second-generation type 2 anti-CD20 inhibitor, more effective — basically a stronger rituximab, approved for use in lupus nephritis.
39:10
They looked at this and what they found was an increase in the urinary epidermal growth factor with treatment, along with improvement in histologic and clinical activity.
39:24
And they found that treatment with obinutuzumab increased the urinary epidermal growth factor separately from the response, and that maybe it was beneficial because it was a benefit seen in the tubules, which don't have an oversized impact on the histopathology analysis.
39:47
So bottom line, I think we're coming closer — with more measures, with novel things like urinary CD163 — to maybe having the liquid biopsy that we have dreamed of, because it's so important in patients with active glomerulonephritis with lupus.
40:04
Yeah, these are intriguing because they sort of shake up the constructs under which we practice.
40:12
And the second one — we don't often have a good way of looking at tubular disease, and it can be just as damaging to the outcomes of renal lupus.
40:23
I think tubular disease and glomerular disease are probably better represented by those past studies that we like to talk about — the urinary biomarkers
40:34
IL-16 and CD163 having highly predictive correlations with histology and outcomes, really putting proteinuria to shame, putting the things that we are working on now
40:53
to shame.
40:54
So I think the lupus community is welcoming these kinds of research.
41:01
I don't think any of us have ever heard of UEGF — urinary epidermal growth factor — but it may become part of our lexicon going forward.
41:14
I think it's incredibly important that we consider this and be open to it and actually push for it, knowing when it's going to really happen.
41:23
So let's see — we've got a few, maybe two more we can get in and then close out with a summary one.
41:37
Ustekinumab in refractory GCA — you know, GCA certainly has IL-6 now, JAK inhibitors are in play, a few years ago the TITAN study targeting
41:50
IL-17 looked great in phase 2 but the phase 3 didn't do well, but yet secukinumab looks good for PMR based on the REPLENISH trial
42:03
studies that may very well lead to FDA approval in the near future.
42:06
But so these other mechanisms should be considered.
42:09
Abstract 1896 from Samson and colleagues was an open-label phase 2B RCT of 36 relapsing GCA patients.
42:22
36 — really, is that the best you can do?
42:26
The interesting thing is when we saw this, we thought, hey, didn't we talk about ustekinumab in GCA in the past?
42:33
Shouldn't this — well, most of the studies were back like before 2020 and they were the same kind of studies — 25 to 30, you know, 32 patients — and they weren't really well controlled at all, but some of them looked good. One of them showed it didn't work.
42:54
So what happened here? 37 relapsing patients either got ustekinumab 90 milligrams — usual dose — with glucocorticoids, or the other group got placebo and glucocorticoids.
43:06
And clearly when they look at the outcome being relapse-free survival, there was a significant advantage for ustekinumab — the lines clearly diverge — but it does take maybe 20 weeks or more before the lines diverge in a survival plot.
43:29
Which is to say that ustekinumab works slow, and you're probably going to need a slow steroid taper in these kinds of patients.
43:37
I think this is encouraging. I don't think there's only one way to skin the cat when it comes to GCA.
43:42
I think we're going to have to get smarter about how we assess and stage these people, as we talked about earlier with clonal hematopoiesis.
43:51
And maybe there will be people that won't respond to the targets that we've currently lined up.
44:01
So I think this is encouraging, but we certainly need more research on this.
44:04
Yeah. I think we're learning more about the diseases from the therapies, and as you said, for PMR and GCA we're looking at JAK inhibitors,
44:12
looking at IL-17 inhibitors — there was a negative study in GCA but that may have been methodologic and may still be viable — and
44:23
the IL-6 inhibitors that we have.
44:25
And maybe this — and remember, ustekinumab is a funny molecule.
44:31
It was developed as an IL-12 inhibitor, and it just happened that the best clone when they did the creation of the monoclonal antibodies blocked P40, which is shared by IL-12 and IL-23.
44:46
And now we have all the P19 — the IL-23 — inhibitors, and ustekinumab is sort of considered like a poor cousin that's a weaker IL-23 inhibitor but it blocks IL-12 as well.
44:59
We don't know whether that's part of it for other diseases like GCA.
45:03
So there's certainly a lot to learn. It's very exciting to have newer therapies, and blocking IL-23 does lead to inhibition of IL-17 as well, so there's a little bit of a tie-in here.
45:16
And of course there are like seven or eight biosimilars of ustekinumab.
45:19
I still wouldn't want to be rushing out to use this — I don't know that we have enough data — but I think there's enough here that we want to see more research, and maybe cheaper drug availability will allow this to happen.
45:30
So let me do one quick last one for me. And this was a late-breaker — late-breaker 12.
45:38
And this is izokibep — I coach her — uh, you can tell by the name it's an inhibitor of a receptor, like anakinra but different.
45:47
Actually, this is an IL-23 receptor blocker that's an oral peptide.
45:54
I know oral peptides are in the news now.
45:57
Everybody wants peptides. I'm not sure I know what a peptide is in this definition — but does it make me want to go to the gym?
46:04
I don't know. But it's cool. But seriously though, this is a very cool idea.
46:10
We all grew up with the idea that monoclonal antibodies were absolutely fantastic.
46:13
But if you try to get them orally, they were food — they were protein and would be digested; you'd absorb none of it.
46:22
Well, now the developments in pharmaceutical science are such that you can deliver peptides orally that do get absorbed and can be effective.
46:34
And I think the one furthest along in this is izokibep, which blocks the IL-23 receptor, and data were presented — it's already approved for skin psoriasis in a number of jurisdictions.
46:47
This looked at patients with psoriatic arthritis, looked at a couple of doses of it, and it worked.
46:53
You absorb some of it — you don't absorb a ton of it.
46:58
It's to be administered on an empty stomach.
47:02
But it's a pill. It's a IL-23 inhibitor in a pill.
47:05
And it raises some interesting questions.
47:06
Is it — do we just lump it in with the other IL-23 inhibitors and say, "Hey, this is a pill version of that, like we do with subcutaneous methotrexate and oral methotrexate"?
47:16
Or are there differences? Are there going to be any safety and efficacy differences?
47:20
It looks like it works, which is just absolutely astounding to those of us old enough to remember when the idea of taking a pill for a peptide was just something you would never ever think of.
47:32
And it's exciting. And I think there's a lot of interest in other targets — IL-17 inhibition, TNF inhibition — in the form of orally administered therapeutic agents.
47:44
A friend of mine just got a dog and I suggested a new name for the dog being Peptide.
47:51
I just think it sounds like a dog's name.
47:56
But the drug is currently approved for psoriasis.
48:00
It's not yet approved in psoriatic arthritis, but they're working towards that.
48:03
And obviously IL-23 inhibition — there are multiple of them out there for both psoriasis and psoriatic arthritis.
48:12
And now the newer thing is that it looks like IL-23 may well work in spondylitis as well.
48:19
So the market here is expanding and we'll see more trials on this.
48:25
And I think it fulfills that need — some patients just do want a pill and don't want to do the injection.
48:35
I started seeing this data two years ago and thought this is really kind of exciting.
48:38
I think it's reached a maturation point that's really quite encouraging.
48:44
So let's end with just a short discussion on the FDA safety update, which was on the third day, chaired by Dr. Michael Weisman.
48:56
The FDA presented new drug approvals, new safety warnings, new package label changes, and they ended with their discussion on avacopan.
49:07
At this meeting there were 12 abstracts on avacopan — five were sponsored by Amgen, the petitioner.
49:14
The story, as you know, begins in January 2026 when the FDA says, "Hey, there's a problem with the ADVOCATE data upon which avacopan was approved."
49:22
And they have communications going back a while with the company about some of these problems with readjudication, improper assignments — rules that were broken that would have halted the drug being approved.
49:37
The FDA requested in March/April of this year that the drug be removed.
49:45
Amgen responded saying no, we want a hearing and we want to present real-world data and whatnot.
49:50
A lot of damning stuff happened in the first part of the year with the FDA basically throwing negative news the way of Amgen.
49:58
Since then we have a lot of abstracts here, but the bottom line is it's a lot of real-world data.
50:07
They show some steroid-sparing. They don't show any real efficacy in real outcomes other than some steroid-sparing — meaning not even less steroid side effects.
50:18
And so therein lies the problem. And there is still this low signal in the real world for hepatotoxicity, and no more reports than the seven cases of vanishing bile duct syndrome seen in Southeast Asia, not in the US.
50:34
So the question is what's happened? The New England Journal revoked — or retracted — the article on ADVOCATE at the request of the authors.
50:45
The EMA removed the drug from the market in the European Union.
50:48
The UK stopped the use of the drug immediately with the plan to fully revoke the drug in the first quarter of 2027.
50:59
So the FDA presented this data and said, "We can't talk about it because the trial's in progress."
51:07
And they have a process that they're going through, but they said in their presentation at least three times that they think this is bad, they think this is something that should lead to the drug being off the market.
51:18
Without saying that they're going to remove it from the market, they said they're working towards that.
51:22
And so Arty, you were in that session. What was your take?
51:25
Yeah, I think the FDA of course has to watch their wording very carefully, but it's a complex issue.
51:34
And as Jack, as you said, you're really balancing the efficacy, and if you're questioning the efficacy — if the efficacy is very low — then your tolerance for adverse events is going to be very low.
51:48
At the extreme other end you think of CAR-T — which we didn't talk about, but there are a bunch of abstracts there — of
51:54
course a super effective therapy in certain diseases but with a lot of very serious side effects, and maybe that's acceptable, like CAR-T in malignant
52:03
diseases, if the outcome is so bad and the effect is very positive.
52:07
But here they're questioning the efficacy.
52:09
And the posters that we saw at the meeting — some of them were, as you said, it's hard to say there was a dramatic signal for efficacy.
52:19
But it is an unmet need — we do have some patients that didn't respond to the standard of care as it was. So really, yeah, very tricky issue.
52:27
All right, folks. I want to end our session by thanking Arty for all the great news and insight.
52:34
I want to let you know that Arty and I are going to be chairing RheumNow Live in Dallas, Texas, January 30 and 31.
52:43
Now is the time for early bird registration.
52:46
It's going to be an exciting day and a half — all day Saturday, half day Sunday, reception Friday night, reception Saturday night, entertainment with a local Texas performer, concert on Saturday night, Mark Cuban as our keynote speaker.
52:59
Our list of faculty is just stellar. I'm really looking forward to this meeting.
53:05
Yeah. And don't forget, Jack — if they come, they'll get a cool t-shirt like this one from last year.
53:11
That's right. It's called RheumNow Live Swag.
53:14
Be there. It'll be fun. Take care. All right. Thanks.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.